InvestorsObserver
Sign Up Login

AYLA Ayala Pharmaceuticals Inc

$1.38 $-0.03 (-2.13%)
Add to Watchlist Compare
Overall

AYLA Stock Analysis Overview

What this means: InvestorsObserver gives Ayala Pharmaceuticals Inc (AYLA) an overall rank of 39, which is below average. Ayala Pharmaceuticals Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 39 means that 61% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

AYLA Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

AYLA Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

AYLA Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

AYLA Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

AYLA Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

AYLA Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

AYLA Stock Analysis Overview

What this means: InvestorsObserver gives Ayala Pharmaceuticals Inc (AYLA) an overall rank of 39, which is below average. Ayala Pharmaceuticals Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 39 means that 61% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full AYLA report

AYLA Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

AYLA Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

AYLA Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

AYLA Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

AYLA Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

AYLA Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Ayala Pharmaceuticals Inc (AYLA) Analyst Forecast

AYLA Price, Volume, Earnings, and Dividend Date

  • Last Price $1.38
  • Previous Close $1.41
  • Change $-0.03
  • Open $1.42
  • Volume 209,770
  • Avg. Volume (100-day) 1,467,758
  • Market Cap 20,379,313
  • Days Range 1.27 - 1.44
  • 52-week Range 0.7 - 14.95
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 11/13/22
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta -6.485
  • PEG Ratio —

Ayala Pharmaceuticals Inc (AYLA) Company Description

Ayala Pharmaceuticals Inc clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The company's current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma-secretase inhibitors. Its product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma-secretase inhibitor, or GSI. It is also developing AL101 for the treatment of T-ALL, an aggressive, rare form of T-cell-specific leukemia.

Ayala Pharmaceuticals Inc (AYLA) Stock Chart

View Interactive AYLA chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Biotechnology

Company Price
Axsome Thera (AXSM) (AXSM) $42.43
Arcutis Biotherapeutics Inc (ARQT) (ARQT) $25.99
Savara Inc (SVRA) (SVRA) $1.64
Pliant Therapeutics Inc (PLRX) (PLRX) $19.89
Trevi Therapeutics Inc (TRVI) (TRVI) $3.75
G1 Therapeutics Inc (GTHX) (GTHX) $12.81
Verona Pharma Plc ADR (VRNA) (VRNA) $12.82
Concert Pharmaceutic (CNCE) (CNCE) $7.03
Dyne Therapeutics Inc (DYN) (DYN) $12.26
Geron Corp (GERN) (GERN) $2.19